Published in Bioorg Med Chem on December 14, 2006
Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol (2009) 1.25
Design and synthesis of L- and D-phenylalanine derived rhodanines with novel C5-arylidenes as inhibitors of HCV NS5B polymerase. Bioorg Med Chem (2013) 0.78
WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth. Cancer Res (2008) 0.77
Development of dimeric modulators for anti-apoptotic Bcl-2 proteins. Bioorg Med Chem Lett (2007) 0.76
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell (2005) 13.59
Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science (1997) 9.73
p53 has a direct apoptogenic role at the mitochondria. Mol Cell (2003) 8.98
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature (1996) 8.37
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science (2004) 7.63
Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A (2000) 3.69
Bcl-2 family proteins. Oncogene (1998) 3.56
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res (2003) 3.52
Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta (2004) 3.47
Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol (2001) 3.03
Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci (2001) 3.03
Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal Biochem (2004) 3.02
Angiogenesis and apoptosis. Semin Cancer Biol (2003) 2.86
Solution structure of the antiapoptotic protein bcl-2. Proc Natl Acad Sci U S A (2001) 2.60
Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol (2001) 2.43
Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. J Biol Chem (2004) 2.12
Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem (2001) 2.06
bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene (1996) 1.87
The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity. EMBO J (2003) 1.59
Apoptosis: biochemical aspects and clinical implications. Clin Chim Acta (2002) 1.54
Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J Biol Chem (1999) 1.52
Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood (1996) 1.47
Conditional deletion of the bcl-x gene from mouse mammary epithelium results in accelerated apoptosis during involution but does not compromise cell function during lactation. Mech Dev (2001) 1.40
Identification of chelerythrine as an inhibitor of BclXL function. J Biol Chem (2003) 1.27
Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res (2000) 1.15
Paralog-selective ligands for bcl-2 proteins. J Am Chem Soc (2005) 1.10
Bcl-2 family members and disease. Biochim Biophys Acta (2004) 1.07
Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer (1999) 1.04
Bcl-w expression in colorectal adenocarcinoma. Br J Cancer (2000) 1.03
Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. Cancer Res (2004) 1.01
Bcl-w is expressed in a majority of infiltrative gastric adenocarcinomas and suppresses the cancer cell death by blocking stress-activated protein kinase/c-Jun NH2-terminal kinase activation. Cancer Res (2003) 0.99
Kaposi's sarcoma tumor cells preferentially express Bcl-xL. Am J Pathol (1996) 0.96
Differential expression of bcl-w and bcl-x messenger RNA in the developing and adult rat nervous system. Neuroscience (1999) 0.93
Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells. Cancer (2005) 0.92
Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Int J Oncol (2003) 0.91
Bcl-2 family gene modulation during spontaneous apoptosis of B-chronic lymphocytic leukemia cells. Biochem Biophys Res Commun (2004) 0.80
Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis. Am J Pathol (2003) 0.79
A critical role for the loop region of the basic helix-loop-helix/leucine zipper protein Mlx in DNA binding and glucose-regulated transcription. Nucleic Acids Res (2006) 1.02
Shared catalysis in virus entry and bacterial cell wall depolymerization. J Mol Biol (2009) 0.96
A continuous fluorescence displacement assay for BioA: an enzyme involved in biotin biosynthesis. Anal Biochem (2011) 0.92
Triazole-linked inhibitors of inosine monophosphate dehydrogenase from human and Mycobacterium tuberculosis. J Med Chem (2010) 0.92
Scaffold rearrangement of dihydroxypyrimidine inhibitors of HIV integrase: Docking model revisited. Bioorg Med Chem Lett (2010) 0.90
Homology modeling and molecular dynamics simulations of the mu opioid receptor in a membrane-aqueous system. Chembiochem (2005) 0.89
N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase. ACS Med Chem Lett (2011) 0.89
3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase. J Med Chem (2011) 0.87
The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus. Bioorg Med Chem (2011) 0.85
Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profiles. Drug Metab Dispos (2006) 0.84
Impact of the C-terminal loop of histidine triad nucleotide binding protein1 (Hint1) on substrate specificity. Biochemistry (2007) 0.82
Pathogenic peptide deviations support a model of adaptive evolution of chordate cardiac performance by troponin mutations. Physiol Genomics (2010) 0.82
6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integrase. Bioorg Med Chem Lett (2011) 0.81
Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylase based on a cinnamic hydroxamic acid core structure. Bioorg Med Chem (2010) 0.81
Dissolution of brominated epoxy resins by dimethyl sulfoxide to separate waste printed circuit boards. Environ Sci Technol (2013) 0.79
pH-responsive titratable inotropic performance of histidine-modified cardiac troponin I. Biophys J (2012) 0.78
Mutations in the amino terminus of herpes simplex virus type 1 gL can reduce cell-cell fusion without affecting gH/gL trafficking. J Virol (2013) 0.78
5-Arylidenethioxothiazolidinones as inhibitors of tyrosyl-DNA phosphodiesterase I. J Med Chem (2012) 0.78
Structure and stability of human telomeric G-quadruplex with preclinical 9-amino acridines. PLoS One (2013) 0.76
Studies of bioactivity, conformation and pharmacokinetic profiles of site-specific PEGylated thymosin alpha 1 derivatives. Drug Metab Lett (2007) 0.75
The Stories Tryptophans Tell: Exploring Protein Dynamics of Heptosyltransferase I from Escherichia coli. Biochemistry (2017) 0.75